Search research articles
Contact Us
Filters
Showing results (111-120 of 189) with videos related to
Page
of 19
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
January 1, 1993
Combination of interleukin-2 and gamma interferon in metastatic renal cell carcinoma
B Escudier, F Farace, E Angevin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 24, 2011
Sexual life of male patients with advanced renal cancer treated with angiogenesis inhibitors
T Bessede, C Massard, B Albouy, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie
|
October 14, 2015
[Not Available]
A Mejean, T Lebret, V Verkarre, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 1, 2009
Diethylstilbestrol (DES) retains activity and is a reasonable option in patients previously treated with docetaxel for castration-resistant prostate cancer
C Serrate, Y Loriot, T De La Motte Rouge, et al.
Prostate Cancer and Prostatic Diseases
|
October 15, 2014
Who dies from prostate cancer?
A Patrikidou, Y Loriot, J-C Eymard, et al.
International Journal of Cancer
|
April 22, 1993
Analysis of T-cell-receptor variable gene segment usage in peripheral-blood lymphocytes of advanced cancer patients
E Angevin, F Farace, C Genevée, et al.
Bulletin Du Cancer
|
December 22, 2009
[New drugs in metastatic castration-resistant prostate cancer]
L Albiges, Y Loriot, M Gross-Goupil, et al.
Genes, Chromosomes & Cancer
|
June 13, 1998
Overrepresentation of 7q31 and 17q in renal cell carcinomas
L Glukhova, A F Goguel, I Chudoba, et al.
British Journal of Cancer
|
March 10, 2011
Levels of circulating CD45(dim)CD34(+)VEGFR2(+) progenitor cells correlate with outcome in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors
F Farace, M Gross-Goupil, E Tournay, et al.
Bulletin Du Cancer
|
April 1, 1995
[Treatment of metastatic kidney neoplasms with a new interleukin 2 protocol: The experience of the Gustave-Roussy Institute]
B Escudier, F Farace, C Théodore, et al.
Page
of 19
Search research articles
Search
Showing results (111-120 of 189) with videos related to
Sort By:
Page
of 19
European Journal of Cancer (Oxford, England : 1990)
|
January 1, 1993
Combination of interleukin-2 and gamma interferon in metastatic renal cell carcinoma
B Escudier, F Farace, E Angevin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 24, 2011
Sexual life of male patients with advanced renal cancer treated with angiogenesis inhibitors
T Bessede, C Massard, B Albouy, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie
|
October 14, 2015
[Not Available]
A Mejean, T Lebret, V Verkarre, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 1, 2009
Diethylstilbestrol (DES) retains activity and is a reasonable option in patients previously treated with docetaxel for castration-resistant prostate cancer
C Serrate, Y Loriot, T De La Motte Rouge, et al.
Prostate Cancer and Prostatic Diseases
|
October 15, 2014
Who dies from prostate cancer?
A Patrikidou, Y Loriot, J-C Eymard, et al.
International Journal of Cancer
|
April 22, 1993
Analysis of T-cell-receptor variable gene segment usage in peripheral-blood lymphocytes of advanced cancer patients
E Angevin, F Farace, C Genevée, et al.
Bulletin Du Cancer
|
December 22, 2009
[New drugs in metastatic castration-resistant prostate cancer]
L Albiges, Y Loriot, M Gross-Goupil, et al.
Genes, Chromosomes & Cancer
|
June 13, 1998
Overrepresentation of 7q31 and 17q in renal cell carcinomas
L Glukhova, A F Goguel, I Chudoba, et al.
British Journal of Cancer
|
March 10, 2011
Levels of circulating CD45(dim)CD34(+)VEGFR2(+) progenitor cells correlate with outcome in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors
F Farace, M Gross-Goupil, E Tournay, et al.
Bulletin Du Cancer
|
April 1, 1995
[Treatment of metastatic kidney neoplasms with a new interleukin 2 protocol: The experience of the Gustave-Roussy Institute]
B Escudier, F Farace, C Théodore, et al.
Page
of 19